August 16, 2005
By Sahar
Bedrood B.S. and Asher Kimchi M.D.
Bern, Switzerland-
Sirolimus-eluting stents and paclitaxel-eluting stents are
used for coronary revascularization and reduce the risk of
restenosis more than bare metal stents. However, until a study
by Stephan Windecker M.D. et al from the University Hospital
Bern in Switzerland, there has been no comparison between the
two types of drug-eluting stents. This study, published in the
August 18, 2005 issue of The New England Journal of Medicine,
found the use of sirolimus-eluting stents results in fewer
major adverse cardiac events than paclitaxel-eluting stents.
The study conducted a randomized,
controlled, single-blind comparison of sirolimus-eluting and
paclitaxel-eluting stents in 1012 patients undergoing
percutaneous coronary intervention. The primary end point was
considered death from cardiac causes, myocardial infarction
and ischemia-driven revascularization of the target lesion by
nine months.
The rate of major
adverse cardiac events at nine months was 6.2 percent in the
sirolimus-stent group and 10.8 percent in the paclitaxel-stent
group. The hazard ratio for the study was 0.56; 95 percent
confidence interval, 0.36 to 0.86; P=0.009. The study
contributed the difference to a lower rate of target-lesion
revascularization in the sirolimus-stent group than in the
paclitaxel-stent group (4.8 percent vs. 8.3 percent; hazard
ratio, 0.56; 95 percent confidence interval, 0.34 to 0.93;
P=0.03).
The rate of death
from cardiac causes was 0.6 percent in the sirolimus-stent
group and 1.6 percent in the paclitaxel-stent group (P=0.15).
The rates of myocardial infarction were 2.8 percent and 3.5
percent, respectively (P=0.49); and the rates of angiographic
restenosis were 6.6 percent and 11.7 percent, respectively
(P=0.02).
In this randomized,
controlled study, the use of sirolimus-eluting stents was
associated with a 44 percent decrease in the risk of major
adverse cardiac events as compared with the use of paclitaxel-eluting
stents. The therapeutic effect of decreasing the rate of
clinical and angiographic restenosis shows support for the use
of sirolimus-eluting stents for coronary revascularization.
Co-authors: Stephan
Windecker, M.D., Andrea Remondino, M.D., Franz R. Eberli,
M.D., Peter Jüni, M.D., Lorenz Räber, M.D., Peter Wenaweser,
M.D., Mario Togni, M.D., Michael Billinger, M.D., David Tüller,
M.D., Christian Seiler, M.D., Marco Roffi, M.D., Roberto Corti,
M.D., Gabor Sütsch, M.D., Willibald Maier, M.D., Thomas
Lüscher, M.D., Otto M. Hess, M.D., Matthias Egger, M.D., and
Bernhard Meier, M.D.
|